Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.

Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Abstract Text:

T Skovsgaard,

Resistance to a new daunorubicin derivative, rubidazone, was developed in a strain of Ehrlich ascites tumor in vivo by treatment with the drug during 11 weekly passages of the tumor. In this tumor reciprocal cross resistance was found between rubidazone, daunorubicin, adriamycin, vincristine, and vinblastine. There was no change in sensitivity of the tumor to methotrexate, 6-mercaptopurine, BCNU, cytosine arabinoside, or actinomycin D. The resistance was stable for at least 71 weeks when treatment was continued and for at least 18 weeks when treatment was discontinued. Rubidazone given intraperitoneally was significantly less toxic than daunorubicin and adriamycin; unlike the findings with daunorubicin and adriamycin, late toxic death (after 30 days) often occurred. In the wild-type tumor the growth inhibition with rubidazone was less than with daunorubicin and adriamycin on an equal weight basis. The LD10 of rubidazone inhibited the growth to nearly the same extent as did the LD10 of daunorubicin and adriamycin.

Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Publishing Authors By Initials

T Skovsgaard,

For similar surgical procedures, operative: transplantation: transplantation, homologous research abstracts see: surgical procedures, operative: transplantation: transplantation, homologous research

PUBMED ID PMID:

MEDLINE DATE: 1975 Mar-Apr

Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Cancer chemotherapy reports. Part 1

VOLUME: 59

Page Numbers: 301-8

Journal Abbreviation:

ISSN: 0069-0112

DAY: 20

MONTH: 02

YEAR: 2008

Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7607105

Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Keywords Mesh Terms:

KEYWORDS: Transplantation, Homologous

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo. Information

Substance Name: Daunorubicin

Registry Number: 20830-81-3

Grant and Affiliation Information for Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cancer Chemother Rep

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Development of resistance to rubidazone NSC-164011 in Ehrlich ascites tumor in vivo Related Publications

• Development of resistance to rubidazone (NSC-164011) in Ehrlich ascites tumor in vivo.
• Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.